AI Quick Summary

🎉 Welcome Hemastatx to our Switzerland Innovation Park Basel Area – Main Campus!Hemastatx, who has recently joined the BaseLaunch portfolio, develops transformative therapies for severe bleeding disorders. Its lead program, HMX001, is a first-in-class antibody therapy for von Willebrand Factor-related disorders. 💬 This is why they picked our Main Campus: "I was really impressed by the vibe on campus; the modern look, state-of-the-art infrastructure, impressive biotech community, and proximity to big pharma make it a unique place."-Kevin Hollevoet, CEO & Co-founder HemastatxWe’re glad to have you with us, Kevin, Karen Vanhoorelbeke, Shannen Deconinck and Nick Geukens! 👏

Post Metadata

• Author: Switzerland Innovation Digital
• Published Date: 6/27/2025 12:56:20 PM
• Modified Date: 6/27/2025 12:56:20 PM

Post Description

🎉 Welcome Hemastatx to our Switzerland Innovation Park Basel Area – Main Campus!

Hemastatx, who has recently joined the BaseLaunch portfolio, develops transformative therapies for severe bleeding disorders. Its lead program, HMX001, is a first-in-class antibody therapy for von Willebrand Factor-related disorders.

💬 This is why they picked our Main Campus:

"I was really impressed by the vibe on campus; the modern look, state-of-the-art infrastructure, impressive biotech community, and proximity to big pharma make it a unique place."

-Kevin Hollevoet, CEO & Co-founder Hemastatx

We’re glad to have you with us, Kevin, Karen Vanhoorelbeke, Shannen Deconinck and Nick Geukens! 👏